🚀 VC round data is live in beta, check it out!
Design Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Design Therapeutics and similar public comparables like Medy-Tox, Neumora Therapeutics, Zhejiang Shouxiangu, Ironwood Pharmaceuticals and more.
Design Therapeutics Overview
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company’s product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Founded
2017
HQ
Employees
54
Website
Sectors
Financials (LTM)
EV
$386M
Design Therapeutics Financials
Design Therapeutics reported last 12-month revenue of —.
In the same LTM period, Design Therapeutics generated — in gross profit and had net loss of ($74M).
Revenue (LTM)
Design Therapeutics P&L
In the most recent fiscal year, Design Therapeutics reported revenue of — and EBITDA of ($79M).
Design Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($79M) | XXX | XXX | XXX |
| Net Profit | ($74M) | XXX | ($70M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Design Therapeutics Stock Performance
Design Therapeutics has current market cap of $591M, and enterprise value of $386M.
Market Cap Evolution
Design Therapeutics' stock price is $10.37.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $386M | $591M | 0.0% | XXX | XXX | XXX | $-1.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDesign Therapeutics Valuation Multiples
Design Therapeutics trades at (4.9x) EV/EBITDA.
EV / Revenue (LTM)
Design Therapeutics Financial Valuation Multiples
As of March 26, 2026, Design Therapeutics has market cap of $591M and EV of $386M.
Equity research analysts estimate Design Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Design Therapeutics has a P/E ratio of (8.0x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $591M | XXX | $591M | XXX | XXX | XXX |
| EV (current) | $386M | XXX | $386M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.9x) | XXX | XXX | XXX |
| EV/EBIT | (4.8x) | XXX | (5.0x) | XXX | XXX | XXX |
| P/E | (8.0x) | XXX | (8.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (7.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Design Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Design Therapeutics Margins & Growth Rates
Design Therapeutics' revenue in the last fiscal year grew by —.
Design Therapeutics' revenue per employee in the last FY averaged $0.0M.
Design Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Design Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medy-Tox | XXX | XXX | XXX | XXX | XXX | XXX |
| Neumora Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| Ironwood Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Replimune Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Design Therapeutics M&A Activity
Design Therapeutics acquired XXX companies to date.
Last acquisition by Design Therapeutics was on XXXXXXXX, XXXXX. Design Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Design Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDesign Therapeutics Investment Activity
Design Therapeutics invested in XXX companies to date.
Design Therapeutics made its latest investment on XXXXXXXX, XXXXX. Design Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Design Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Design Therapeutics
| When was Design Therapeutics founded? | Design Therapeutics was founded in 2017. |
| Where is Design Therapeutics headquartered? | Design Therapeutics is headquartered in United States. |
| How many employees does Design Therapeutics have? | As of today, Design Therapeutics has over 54 employees. |
| Who is the CEO of Design Therapeutics? | Design Therapeutics' CEO is Pratik Shah. |
| Is Design Therapeutics publicly listed? | Yes, Design Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Design Therapeutics? | Design Therapeutics trades under DSGN ticker. |
| When did Design Therapeutics go public? | Design Therapeutics went public in 2021. |
| Who are competitors of Design Therapeutics? | Design Therapeutics main competitors are Medy-Tox, Neumora Therapeutics, Zhejiang Shouxiangu, Ironwood Pharmaceuticals. |
| What is the current market cap of Design Therapeutics? | Design Therapeutics' current market cap is $591M. |
| Is Design Therapeutics profitable? | No, Design Therapeutics is not profitable. |
| What is the current net income of Design Therapeutics? | Design Therapeutics' last 12 months net income is ($74M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.